hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06345599 id: LK2023100 briefTitle: PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study) overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-01-10 date: 2027-01-10 date: 2024-04-03 date: 2024-04-03 name: Second Affiliated Hospital of Soochow University class: OTHER briefSummary: The goal of this clinical trial is to learn about Phase I+Phase II Clinical Study of PRaG Therapy in Combination With Chemotherapy (AG Regimen) for Neoadjuvant Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study).The main question it aims to answer is to investigate the safety and efficacy of the PRaG treatment modality combined with chemotherapy neoadjuvant therapy for locally advanced pancreatic cancer. conditions: Pancreatic Ductal Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 66 type: ESTIMATED name: Radiotherapy name: Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab name: Chemotherapy:Albumin-bound paclitaxel、Gemcitabine measure: Adverse events measure: Serious adverse events measure: 1-year overall survival measure: Objective response rate measure: Disease control rate measure: Overall survival measure: R0 resection rate measure: Progression free survival sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-09-22 uploadDate: 2024-03-26T10:41 filename: Prot_SAP_000.pdf size: 1237855 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-11-27 uploadDate: 2024-03-26T10:44 filename: ICF_001.pdf size: 376918 hasResults: False
nctId: NCT06345586 id: 078066 briefTitle: Drospirenone Only Pills and Cervical Mucus Changes: A Pre- and Post-Bariatric Surgery Study overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-04-03 date: 2024-04-03 name: Chulalongkorn University class: OTHER briefSummary: The purpose of this study is to study the effect of Drospirenone on cervical mucus change by modified Insler score, pre-bariatric surgery and post-bariatric surgery conditions: Contraception studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Participants received Drospirenone will be assess for cervical mucus change by modified Insler score primaryPurpose: BASIC_SCIENCE masking: NONE count: 16 type: ESTIMATED name: Drospirenone measure: Cervical mucus by modified Insler score measure: Estrogen and progesterone levels versus time measure: Number of Participants With Treatment-Related Adverse Events sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Chulalongkorn University city: Bangkok zip: 10330 country: Thailand lat: 13.75398 lon: 100.50144 hasResults: False
nctId: NCT06345560 id: 077766 briefTitle: Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-04-03 date: 2024-04-03 name: Chulalongkorn University class: OTHER briefSummary: The purpose of this study is to investigate whether bariatric surgery affects Drospirenone only pills absorption conditions: Contraception studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Pre-bariatric surgery pharmacokinetics study of Drospirenone compare with post-bariatric surgery primaryPurpose: BASIC_SCIENCE masking: NONE count: 16 type: ESTIMATED name: Drospirenone measure: Plasma concentration versus Time of Drospirenone measure: Number of Participants With Treatment-Related Adverse Events sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Chulalongkorn University city: Bangkok zip: 10330 country: Thailand name: Punyawee Utaipatanacheep role: CONTACT lat: 13.75398 lon: 100.50144 hasResults: False
nctId: NCT06345547 id: EDGE 003539 briefTitle: Muscle Mass Via UltraSound in Cirrhosis (MMUSCLE) acronym: MMUSCLE overallStatus: NOT_YET_RECRUITING date: 2024-05-02 date: 2026-05-02 date: 2027-05-31 date: 2024-04-03 date: 2024-04-03 name: University Hospital, Antwerp class: OTHER briefSummary: The goal of this observational cohort study is to learn about loss of muscle mass and muscle strength (sarcopenia) in patients with cirrhosis. The main question\[s\] it aims to answer are:
* complete a questionnaire to assess quality of life conditions: Sarcopenia conditions: Cirrhosis conditions: Malnutrition studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: ultrasound measure: Prevalence of sarcopenia: muscle mass measure: Prevalence of sarcopenia: muscle strength measure: Development of sarcopenia: changes in muscle mass measure: Development of sarcopenia: changes in muscle strength measure: Development of sarcopenia: changes in muscle quality measure: Decompensation events: MELD score • MELD evolution measure: Decompensation events: mortality • MELD evolution measure: Decompensation events: transplantation • MELD evolution measure: Malnutrition measure: Quality of life in cirrhosis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Antwerp city: Edegem state: Antwerpen zip: 2650 country: Belgium name: Karolien Dams, MD role: CONTACT phone: +3238213635 phoneExt: 5175 email: karolien.dams@uza.be name: Jolien Derdeyn, MD role: CONTACT phone: +328213807 phoneExt: 3807 email: jolien.derdeyn@uza.be name: Jolien Derdeyn, MD role: SUB_INVESTIGATOR name: Thomas Vanwolleghem, MD, Phd role: SUB_INVESTIGATOR name: Philippe Jorens, MD, PhD role: SUB_INVESTIGATOR name: Stany Perkisas, MD, PhD role: SUB_INVESTIGATOR name: Karolien Dams, MD role: PRINCIPAL_INVESTIGATOR lat: 51.15662 lon: 4.44504 hasResults: False
nctId: NCT06345534 id: ONZ-2023-0255 briefTitle: FAST-FORWARD vs HAI5 overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2033-12-31 date: 2033-12-31 date: 2024-04-03 date: 2024-04-03 name: University Hospital, Ghent class: OTHER briefSummary: Randomized comparison between the FAST-FORWARD schedule and the HAI5 schedule for breast cancer radiotherapy in 5 fractions. conditions: Cancer, Breast studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients participating in the study will be randomized 1:1 between the FAST-FORWARD schedule and the HAI5 schedule. The first group is treated according to the FAST-FORWARD schedule, consisting of 5 radiation sessions on 5 consecutive working days (e.g. Monday to Friday). 2 rest days are allowed in the schedule, so that the treatment lasts a maximum of 7 days. The second group is treated according to the HAI5 schedule, developed by the radiotherapy department of Ghent University Hospital. In this schedule, at least 1 day of rest is scheduled between each treatment session, so the treatment is administered over 10-14 days. primaryPurpose: TREATMENT masking: NONE maskingDescription: Both healthcare provider and patient know the treatment count: 740 type: ESTIMATED name: Questionnaire measure: Early side effects sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Universitary Hospital city: Ghent zip: 9000 country: Belgium name: Liv Veldeman, MD, PhD role: CONTACT phone: 09 332 30 15 email: liv.veldeman@uzgent.be name: Emma Van Damme, MD role: CONTACT phone: 09 332 19 53 email: emma.vandamme@uzgent.be lat: 51.05 lon: 3.71667 hasResults: False
nctId: NCT06345521 id: 2022-1-4032-3 briefTitle: The Follow-up System of Pediatric Heart Failure and the Establishment of End-stage Heart Failure Registry overallStatus: RECRUITING date: 2022-01-01 date: 2024-06-22 date: 2024-12-31 date: 2024-04-03 date: 2024-04-03 name: China National Center for Cardiovascular Diseases class: OTHER_GOV name: Peking University First Hospital name: Beijing Children's Hospital briefSummary: Establish a follow-up management system for pediatric heart failure and a registration platform for end-stage heart failure conditions: Heart Failure conditions: Congenital conditions: End-stage Heart Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: No intervention measure: the recurrence rate of heart failure measure: NT-proBNP level measure: Incidence rate of drug adverse reactions measure: Readmission rate for heart failure sex: ALL maximumAge: 14 Years stdAges: CHILD facility: Fuwai hospital status: RECRUITING city: Beijing country: China name: Shoujun Li, MD role: CONTACT phone: +86 13501071589 email: drlishoujunfw@163.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06345495 id: 2023-0899 id: NCI-2024-02814 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly overallStatus: NOT_YET_RECRUITING date: 2024-09-30 date: 2027-01-01 date: 2029-01-01 date: 2024-04-03 date: 2024-04-03 name: M.D. Anderson Cancer Center class: OTHER name: Incyte Corporation briefSummary: To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed. conditions: Splenomegaly conditions: Myelofibrosis studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Ruxolitinib name: Allogeneic Stem Cell Transplantation name: Levetiracetam name: Eltrombopag name: Busulfan name: Romiplostim name: Fludarabine phosphate name: Cyclophosphamide name: Mesna name: Tacrolimus measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06345482 id: MHB039A-A-101 briefTitle: A Study of MHB039A for Advanced Solid Tumor overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2028-04-01 date: 2029-06-01 date: 2024-04-03 date: 2024-04-03 name: Minghui Pharmaceutical (Hangzhou) Ltd class: INDUSTRY briefSummary: Phase I/II open label, multicenter study to evaluate the efficacy and safety of MHB039A in advanced malignant tumors. conditions: Advanced Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 196 type: ESTIMATED name: MHB039A measure: Incidence of participants with adverse events (AE) measure: Number of participants with dose-limiting toxicity (DLT) measure: Maximum Plasma Concentration (Cmax) of MHB039A measure: The area under the plasma concentration-time curve (AUC) of MHB039A measure: To detectable anti-drug antibodies with treated subjects measure: Objective response rate (ORR) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Chest Hospital city: Shanghai state: Shanghai zip: 200030 country: China name: Shun Lu, MD role: CONTACT phone: 13601813062 email: shun_lu@hotmail.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06345469 id: O-PBM2 briefTitle: Cost Analysis of Therapies for Severe Anemia overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-04-01 date: 2026-05-01 date: 2024-04-03 date: 2024-04-03 name: Helios Klinik Gotha/Ohrdruf class: OTHER name: Marisa Eichner briefSummary: The goal of this observational study is to learn about the costs that occur when participants with severe anemia are treated with blood transfusions or with patient blood management (PBM). PBM means that the body of the participant is stimulated to produce new blood by itself rather than receiving it from a blood donor, and to reduce blood losses.
The main question the study aims to answer is: Do participants treated with transfusions incur the same treatment costs than participants treated with PBM? And how much costs are this in relation to the lives saved by the therapy of severe anemia? conditions: Severe Anemia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 640 type: ESTIMATED name: Patient blood management (PBM) name: Allogeneic transfusion measure: cost-effectiveness sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06345456 id: izmirkatip briefTitle: The Value of End-tidal Capnography in Gastrointestinal Bleeding overallStatus: COMPLETED date: 2020-06-01 date: 2021-01-01 date: 2021-01-01 date: 2024-04-03 date: 2024-04-08 name: Izmir Katip Celebi University class: OTHER briefSummary: Gastrointestinal bleeding is a condition that frequently presents to emergency departments and can be fatal if diagnosis and treatment are delayed. The working mechanism of end tidal capnography is simply to detect the respiratory carbon dioxide level.
In our study, the investigators aimed to determine the severity of gastrointestinal bleeding by using the Glaskow Blachford Score and AIMS65 score in cases presenting with gastrointestinal bleeding, to determine the end tidal carbon dioxide value by capnography in these cases and to determine its effectiveness in evaluating mortality and morbidity in gastrointestinal bleeding. conditions: Gastro Intestinal Bleeding studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 103 type: ACTUAL name: End-tidal capnography measure: The correlation between ETCO2 value and mortality in patients with gastrointestinal bleeding will be investigated. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Katip Çelebi Üniversitesi city: İzmir country: Turkey lat: 38.41273 lon: 27.13838 typeAbbrev: SAP hasProtocol: False hasSap: True hasIcf: False label: Statistical Analysis Plan date: 2020-06-01 uploadDate: 2024-04-01T04:48 filename: SAP_000.pdf size: 281538 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2020-06-01 uploadDate: 2024-04-01T04:35 filename: ICF_001.pdf size: 418132 hasResults: False
nctId: NCT06345443 id: 23-005288 briefTitle: NRM on Vascular Perfusion in Heathy Adults acronym: NRM overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-12-31 date: 2026-05-31 date: 2024-04-03 date: 2024-04-03 name: Mayo Clinic class: OTHER briefSummary: The purpose of this study is to better understand the effects of nicotinamide riboside supplement in overall cardiovascular health in healthy adults. conditions: Vascular Stiffness studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE maskingDescription: The pharmacy will be responsible for randomization and dispensing appropriate randomized intervention. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 200 type: ESTIMATED name: Nicotinamide Riboside Malate name: Placebo measure: Reduction of Endothelial stiffness sex: ALL minimumAge: 40 Years maximumAge: 60 Years stdAges: ADULT facility: Mayo Clinic in Rochester city: Rochester state: Minnesota zip: 55905 country: United States name: Snigdha Panda, BS role: CONTACT phone: 507-538-5827 email: GIMRESEARCHSTUDIES@mayo.edu name: Jennifer Soderlind role: CONTACT phone: 507-284-4799 email: GIMRESEARCHSTUDIES@mayo.edu lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06345430 id: 2023-14 briefTitle: Wearable Technological Device Applied to Patients With Chronic Pain overallStatus: COMPLETED date: 2023-11-18 date: 2024-01-15 date: 2024-01-30 date: 2024-04-03 date: 2024-04-03 name: Hacettepe University class: OTHER briefSummary: Within the scope of this research, a single session of Wearable Technological Device (Exopulse Molli-Suit) will be applied to patients with chronic back and neck pain. The results will be evaluated acutely, after 24 hours, after 1 week and after 1 month. conditions: Neck Pain conditions: Low Back Pain conditions: Chronic Pain conditions: Musculoskeletal Pain studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ACTUAL name: Exopulse Molli-Suit (Wearable Technological Device) measure: Pain Severity measure: Sleep Qaulity measure: Disability Level measure: Repetitive Reach Test measure: Body Composition Analysis measure: Lifting object overhead test measure: Sustained Overhead Work Test measure: back performance test sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yasemin Özel Aslıyüce city: Yeni̇mahalle state: Ankara zip: 06100 country: Turkey hasResults: False
nctId: NCT06345417 id: O-PBM1 briefTitle: Outcomes of Patient Blood Management in Severely Anemic Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2025-05-01 date: 2024-04-03 date: 2024-04-03 name: Helios Klinik Gotha/Ohrdruf class: OTHER name: Helios Klinikum Erfurt briefSummary: The goal of this observational cohort study is to compare patients with very low red blood counts who receive different therapy. Its main question\[s\] it aims to answer are:
* Among these groups: which group of patients has more complications during hospital stay? Patients will either receive patient blood management, which is the management of anemia, bleeding and coagulation problems, will receive transfusions, that is, blood from other people, or a mix of both. conditions: Severe Anemia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 20000 type: ESTIMATED name: Patient Blood Management (PBM) name: Allogeneic transfusion measure: Number of dead participants at the end of hospitalization (inhospital mortality) measure: Number of participants with surgical wound complications measure: Number of participants with a documented acute myocardial infarction measure: Number of participants suffering renal injury measure: Number of days spent in hospital (Length of stay in hospital) measure: Number of participants readmitted to the studied hospital measure: Number of participants with a documented transfusion reaction measure: Number of participants receiving an allogeneic transfusion measure: Number of participants treated in an intensive care ward measure: Number of participants with documented respiratory complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Helios Klinikum city: Erfurt state: Thuringia country: Germany name: Achim Spenner role: CONTACT phone: +49-361-7810 email: Achim.Spenner@helios-gesundheit.de lat: 50.9787 lon: 11.03283 facility: Helios Klinikum city: Gotha state: Thuringia zip: 99867 country: Germany name: Petra See role: CONTACT phone: +49-3621-220 0 email: petra.seeber@helios-gesundheit.de name: Kai D role: CONTACT phone: +49-3621-220 phoneExt: 5058 email: Kai-uwe.doebel@helios-gesundheit.de lat: 50.94823 lon: 10.70193 hasResults: False
nctId: NCT06345404 id: CPI-818-003 briefTitle: Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD overallStatus: RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-04-03 date: 2024-04-10 name: Corvus Pharmaceuticals, Inc. class: INDUSTRY briefSummary: Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD conditions: Atopic Dermatitis studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Sequential Dose Escalation primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Blinded Placebo-Controlled whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 64 type: ESTIMATED name: Soquelitinib name: Placebo measure: Incidence of adverse events, changes in laboratory values, vital signs, and electrocardiograms measure: To determine the efficacy of soquelitinib in participants with atopic dermatitis as measured by percent change in Eczema and Severity Index (EASI) measure: To determine the efficacy of soquelitinib in participants with atopic dermatitis as measured by change in percent reaching validated Investigator Global Assessment (vIGA) of 0 or 1 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Corvus Clinical Trials Information status: RECRUITING city: Burlingame state: California zip: 94010 country: United States name: Liza Tom role: CONTACT phone: 650-900-4514 email: ltom@corvuspharma.com name: Gabriel Luciano role: CONTACT phone: 6509004548 email: gluciano@corvuspharma.com lat: 37.5841 lon: -122.36608 hasResults: False
nctId: NCT06345391 id: PANACEA_CO-CREATION_2024 briefTitle: Co-creation of Pain Science Education for Children Living Beyond Cancer acronym: PANACEA overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-09 date: 2024-09 date: 2024-04-03 date: 2024-04-03 name: Vrije Universiteit Brussel class: OTHER name: Universitair Ziekenhuis Brussel name: University Ghent name: University Hospital, Ghent name: University of Calgary briefSummary: A pain science education (PSE) intervention for children (8-12y) living beyond cancer (CBC) will be developed through a co-creational approach with CBC, their parents and pediatric oncology clinicians. The study will be guided by the Intervention Mapping Protocol. conditions: Children Living Beyond Cancer (i.e. Child Cancer Survivor) studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 24 type: ESTIMATED name: Co-creation name: Concept Mapping measure: Satisfaction with the co-created intervention measure: Understandability of the co-created intervention measure: Empowerment with regard to the co-created intervention measure: Ownership of the intervention development sex: ALL minimumAge: 8 Years maximumAge: 12 Years stdAges: CHILD facility: Vrije Universiteit Brussel city: Jette state: Brussels zip: 1090 country: Belgium name: Emma Rheel, PhD role: CONTACT phone: +32496908353 email: emma.rheel@vub.be name: Kelly Ickmans, PhD role: CONTACT phone: +32498483347 email: kelly.ickmans@vub.be name: Sophie Pleysier, MSc role: SUB_INVESTIGATOR lat: 50.87309 lon: 4.33419 hasResults: False
nctId: NCT06345378 id: IRFMN_PapaGio briefTitle: Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Admissions of Patients Accessing the Emergency Department (ASST Papa Giovanni XXIII) overallStatus: ACTIVE_NOT_RECRUITING date: 2021-11-25 date: 2024-12 date: 2027-12 date: 2024-04-03 date: 2024-04-04 name: Mario Negri Institute for Pharmacological Research class: OTHER briefSummary: The aim of this study is to develop, study and validate a rigorous and sustainable method for assessing the clinical appropriateness of the decision taken in the Emergency Department to admit or not to admit patients. conditions: Quality of Care conditions: Evaluation conditions: Emergency Departments conditions: Appropriateness studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1200 type: ESTIMATED measure: Algorithm creation measure: Algorithm validation measure: Algorithm application measure: Appropriateness estimation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ASST Papa Giovanni XXIII city: Bergamo state: BG zip: 24127 country: Italy lat: 45.69601 lon: 9.66721 hasResults: False